However, Johnson & Johnson has a 'savior' in its neuroscience portfolio, namely Spravato (esketamine), which is the NMDA receptor antagonist. Moreover, on January 21, 2025, the FDA approved Spravato ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback